MedTrace Logo

Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome

NCT01329770 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-04-14

No results posted yet for this study

Summary

The Fragile X syndrome (FXS) was first described by Dr. Martin and Dr. Bell in 1943, in families with several patients affected by sex-linked mental disability. This disorder is the most common cause of inherited mental disability. The prevalence of the Fragile X syndrome has been established at 1 in 2,500 males and 1 in 4000 females.

Despite moderate to severe mental retardation, fragile X patients exhibit macroorchidism, an elongated face, long ears, connective tissue dysplasia, hyperactivity, autistic-like and stereotypical behaviours, speech delay and increased sensory sensitivity.

Objective: To evaluate the effect of the combination of the antioxidant Ascorbic acid and tocopherol, as therapy of the Fragile X Syndrome in young males.

Hypothesis: It is proposed that part of the pathophysiology of the central nervous system in the animal model of the fragile X syndrome may be determined by oxidative stress. In addition, Fragile X patients showed a significantly low level of ascorbic acid in plasma. The biochemical characteristics of oxidative stress may be reversed in the FMR1-KO mice, by a chronic treatment with antioxidant compounds such as tocopherol or melatonin, it may also normalize several hallmarks of the Syndrome such as hyperactivity, anxiety and cognitive deficits. The normalization of the oxidative stress is proposed as a new therapeutic pathway to alleviate conditions caused by an excess of free radicals that are crucial in neurodevelopmental diseases such as autism, down syndrome and other diseases of the central nervous system.

Conditions

  • Fragile X Syndrome

Interventions

DIETARY_SUPPLEMENT

Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)

* Vitamin E (D-alpha-Tocopherol) 10 mg/kg/day (with a maximum of 600mg/day) * Vitamin C (L-Ascorbic Acid) 10 mg/kg/day (with a maximum of 800mg/day) For 12 weeks

DIETARY_SUPPLEMENT

Placebo

Two daily dose of placebo, administered at breakfast and dinner for 12 weeks

Sponsors & Collaborators

  • Yolanda de Diego Otero

    lead OTHER

Principal Investigators

  • Yolanda de Diego Otero, PhD · IMABIS Foundation. Hospital Carlos Haya. Malaga

  • Lucia M Perez Costillas, MD PhD · Hospital Carlos Haya. Malaga

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01329770 on ClinicalTrials.gov